Loading…
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.4B | $337M | $168M | $142M | 20.4% | 4.0% | 42.6% |
| 2024 | $1.3B | $262M | $118M | $144M | 12.2% | 12.0% | 1.9% |
| 2023 | $1.2B | $249M | $115M | $82M | 14.1% | 17.7% | 166.1% |
| 2022 | $993M | $178M | $43M | $76M | 5.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 993.20 | 1,168.66 | 1,309.06 | 1,360.82 |
| Cost Of Revenue | 487.69 | 553.56 | 617.51 | 611.87 |
| Gross Profit | 505.50 | 615.10 | 691.55 | 748.96 |
| Operating Expense | 434.36 | 459.45 | 518.25 | 547.77 |
| Operating Income | 71.15 | 155.65 | 173.30 | 201.19 |
| EBITDA | 178.50 | 249.34 | 262.10 | 337.40 |
| EBIT | 80.75 | 156.03 | 164.88 | 221.82 |
| Pretax Income | 63.63 | 141.40 | 151.87 | 212.07 |
| Tax Provision | 20.25 | 26 | 34.31 | 44.39 |
| Net Income | 43.38 | 115.40 | 117.56 | 167.68 |
| Net Income Common Stockholders | 43.38 | 115.40 | 117.56 | 167.68 |
| Total Expenses | 922.05 | 1,013.01 | 1,135.75 | 1,159.64 |
| Interest Expense | 17.12 | 14.63 | 13.02 | 9.75 |
| Research And Development | 46.80 | 50.13 | 54.44 | 62.72 |
| Selling General And Administration | 340.14 | 376.68 | 431.78 | 436.79 |
| Normalized EBITDA | 168.89 | 248.96 | 270.52 | 316.77 |
| Normalized Income | 36.83 | 115.09 | 124.07 | 151.36 |
| Basic EPS | 0.85 | 2.27 | 2.32 | 3.33 |
| Diluted EPS | 0.84 | 2.24 | 2.29 | 3.31 |
| Tax Effect Of Unusual Items | 3.06 | 0.07 | -1.90 | 4.31 |
| Tax Rate For Calcs | 0.32 | 0.18 | 0.23 | 0.21 |
| Total Unusual Items | 9.60 | 0.38 | -8.42 | 20.63 |
| Total Unusual Items Excluding Goodwill | 9.60 | 0.38 | -8.42 | 20.63 |
| Net Income From Continuing Operation Net Minority Interest | 43.38 | 115.40 | 117.56 | 167.68 |
| Reconciled Depreciation | 97.75 | 93.31 | 97.22 | 115.59 |
| Reconciled Cost Of Revenue | 437.36 | 492.90 | 552.32 | 544.54 |
| Net Interest Income | -17.12 | -14.63 | -13.02 | -9.75 |
| Net Income From Continuing And Discontinued Operation | 43.38 | 115.40 | 117.56 | 167.68 |
| Total Operating Income As Reported | 80.75 | 156.03 | 164.88 | 221.82 |
| Diluted Average Shares | 51.35 | 51.42 | 51.40 | 50.73 |
| Basic Average Shares | 51.05 | 50.78 | 50.71 | 50.33 |
| Diluted NI Availto Com Stockholders | 43.38 | 115.40 | 117.56 | 167.68 |
| Net Income Including Noncontrolling Interests | 43.38 | 115.40 | 117.56 | 167.68 |
| Net Income Continuous Operations | 43.38 | 115.40 | 117.56 | 167.68 |
| Other Income Expense | 9.60 | 0.38 | -8.42 | 20.63 |
| Special Income Charges | 9.60 | 0.38 | -8.42 | 20.63 |
| Gain On Sale Of Business | 9.60 | 0.38 | 2 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 10.42 | 2.39 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | -23.02 |
| Net Non Operating Interest Income Expense | -17.12 | -14.63 | -13.02 | -9.75 |
| Interest Expense Non Operating | 17.12 | 14.63 | 13.02 | 9.75 |
| Depreciation Amortization Depletion Income Statement | 47.41 | 32.64 | 32.03 | 48.26 |
| Depreciation And Amortization In Income Statement | 47.41 | 32.64 | 32.03 | 48.26 |
| Amortization | 47.41 | 32.64 | 32.03 | 48.26 |
| Amortization Of Intangibles Income Statement | 47.41 | 32.64 | 32.03 | 48.26 |
| Operating Revenue | 993.20 | 1,168.66 | 1,309.06 | 1,360.82 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Haemonetics Corporationthis co. | HAE | $2.7B | 16.26↓ discount | 3.03 | 20.4% | 9.88 |
| LifeStance Health Group, Inc. | LFST | $2.9B | 371.50 | 1.90 | 0.6% | 39.06 |
| Dyne Therapeutics, Inc. | DYN | $2.9B | - | 2.95 | -45.9% | -4.14 |
| Erasca, Inc. | ERAS | $2.8B | - | 7.96 | -38.3% | -20.28 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.8B |
| - |
| 14.56 |
| -8.5% |
| -352.93 |
| Soleno Therapeutics, Inc. | SLNO | $2.7B | 135.33 | 6.13 | 4.6% | 145.68 |
| Kodiak Sciences Inc. | KOD | $2.7B | - | 17.11 | -146.1% | -11.78 |
| Warby Parker Inc. | WRBY | $2.6B | 2147.00 | 7.15 | 0.4% | 56.61 |
| Tarsus Pharmaceuticals, Inc. | TARS | $2.6B | - | 7.52 | -19.3% | -32.50 |
| Peer Median | - | 371.50 | 7.33 | -13.9% | -7.96 | |